Oncopeptides AB
STO:ONCO

Watchlist Manager
Oncopeptides AB Logo
Oncopeptides AB
STO:ONCO
Watchlist
Price: 5.17 SEK -3.18% Market Closed
Market Cap: 1.3B SEK

Intrinsic Value

The intrinsic value of one ONCO stock under the Base Case scenario is 4.37 SEK. Compared to the current market price of 5.17 SEK, Oncopeptides AB is Overvalued by 15%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ONCO Intrinsic Value
4.37 SEK
Overvaluation 15%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Oncopeptides AB

What is Valuation History?
Ask AI Assistant
What other research platforms think about ONCO?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is ONCO valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Oncopeptides AB.

Explain Valuation
Compare ONCO to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about ONCO?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Oncopeptides AB

Current Assets 191.4m
Cash & Short-Term Investments 147.9m
Receivables 35m
Other Current Assets 8.4m
Non-Current Assets 19.9m
PP&E 19.9m
Current Liabilities 56m
Accounts Payable 12.2m
Other Current Liabilities 43.7m
Non-Current Liabilities 148.8m
Long-Term Debt 126.2m
Other Non-Current Liabilities 22.6m
Efficiency

Free Cash Flow Analysis
Oncopeptides AB

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Oncopeptides AB

Revenue
62.6m SEK
Cost of Revenue
-1.3m SEK
Gross Profit
61.3m SEK
Operating Expenses
-307.7m SEK
Operating Income
-246.5m SEK
Other Expenses
-21.4m SEK
Net Income
-267.8m SEK
Fundamental Scores

ONCO Profitability Score
Profitability Due Diligence

Oncopeptides AB's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

Exceptional 3Y Average ROE
ROIC is Increasing
Exceptional Gross Margin
Strong 3Y Average Gross Margin
37/100
Profitability
Score

Oncopeptides AB's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

ONCO Solvency Score
Solvency Due Diligence

Oncopeptides AB's solvency score is 30/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Long-Term Solvency
High D/E
30/100
Solvency
Score

Oncopeptides AB's solvency score is 30/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ONCO Price Targets Summary
Oncopeptides AB

Wall Street analysts forecast ONCO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ONCO is 5.29 SEK with a low forecast of 5.24 SEK and a high forecast of 5.44 SEK.

Lowest
Price Target
5.24 SEK
1% Upside
Average
Price Target
5.29 SEK
2% Upside
Highest
Price Target
5.44 SEK
5% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Oncopeptides AB
does not pay dividends
Shareholder Yield

Current shareholder yield for ONCO is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one ONCO stock?

The intrinsic value of one ONCO stock under the Base Case scenario is 4.37 SEK.

Is ONCO stock undervalued or overvalued?

Compared to the current market price of 5.17 SEK, Oncopeptides AB is Overvalued by 15%.

Back to Top